Clinical Observation Of Intravitreal Injection Of Lucentis On The Treatment For Macular Edema Secondary To Central Retinal Vein Occlusion

Purpose: To observe the clinical effect of intravitreal injection of Lucentis on thetreatment for macular edema secondary to central retinal vein occlusion.Methods: Thirty cases（30Eyes） of patients with macular edema secondary toischemic central retinal vein occlusion,which were diagnosed by fundus fluoresceinangiography（FFA） and optical coherence tomography（OCT） and have been treatedby retinal photocoagulation,were randomly divided into injection group （15cases,15eyes） and control group（15cases,15eyes）.The injection group was treated withintravitreal injection of0.5mg Lucentis,and the control group received regular follow-upobservation.During2months follow-up period,the best corrected visual acuity（BCVA）and central macular thickness（CMT） of1w,1m and2m were observed and recorded.Results: In the injection group, the mean best corrected visual acuity（BCVA）were0.93±0.07,0.52±0.08,0.29±0.10and0.35±0.10before and after treatment for1w,1m and2m,respectively;the CMT were719.80±183.00μ m,336.60±183.89μ m,257.93±69.85μm and262.27±108.34μm before and after treatment for1w,1m and2m,respectively. The BCVA during the treatment was significant increased compared to thatof pretreatment（P<0.01）;the BCVA of1m and2m was significant increased comparedto that of1w（P<0.01）;there was no significant difference with respect to the increase inthe visual acuity between1m and2m（P>0.05）. The CMT during the treatment wassignificant decreased compared to that of pretreatmen（tP<0.01）;the CMT of1m and2mwas significant decreased compared to that of1w（P<0.01）;there was no significantdifference with respect to the decrease in the central macular thickness between1m and 2m（P>0.05）.In the control group, the mean BCVA were0.91±0.08,0.92±0.08,0.93±0.07and0.93±0.08before and after follow-up for1w,1m and2m, respectively; the mean CMTwere748.13±147.09μm,737.87±136.75μm,747.20±151.90μm and744.80±154.85μmbefore and after follow-up for1w,1m and2m, respectively. There was no significantdifference with respect to the increase in the visual acuity and decrease in the centralmacular thickness among all time points before and after follow-up observation（P>0.05）.There was significant difference with respect to the increase in the visual acuityand decrease in the central macular thickness between the injection group and thecontrol group（P<0.01）.None of servere ocular complications such as glaucoma, endophthalmitis, cataract,cyclodialysis detachment, retinal detachment and systemic adverse reactions associatedwith drugs happened during the treatment with intravitreal injection of Lucentis.Conclusions: Intravitreal injection of Lucentis on the treatment for macular edemasecondary to central retinal vein occlusion caused a significant increase in visual acuityand decrease in central macular thickness in a short term. It is a safe and reliable therapy,which provides new ideas for clinical treatment of macular edema secondary to centralretinal vein occlusion, but its long-term efficacy remains to be further observed.